Aug 31-02, 2023    London, UK
5th International Conference on

Dementia and Dementia Care

About Dementia 2023

We are extremely indebted to invite you to attend the 5th International Conference on Dementia and Dementia Care on August 31-02 in London, UK. Dementia 2023 is planned in a way that marks its notation on various important sessions on dementia and dementia care that includes its stages, the different arena of causes, treatment advancements, and awareness techniques. It is also a platform for all the innovators, researchers, organizations, scholars, and caretakers to discuss and exhibit the recent advancements in the diagnosis, care, and management of Dementia and it also brings together the researchers to dissertate novel drug discovery, and technical development in care methods, on-going clinical trials, future developments in the therapies.

The conference will extend a platform for the multidisciplinary exchange of information among people from different regions of the world and get insights into such scientific discoveries in all aspects. It will not only help you expand your horizon for associating with colleagues and eminent speakers but also build global-level collaborations in a futuristic manner.

Reasons to attend Dementia 2023

- Networking opportunities
- Insights on future developments in technologies
- Presenting your ideas before pioneers
- Enriching workshops and exhibitions
- Professional knowledge upgrade

Target Audience

- Neurologists
- Geriatricians
- Clinical Neurologist
- Geriatric Psychiatrists
- Speech Therapists
- Research Faculty
- Scientists and professors
- Physical Therapists
- Nurses
- Health Organizations
- Social Workers
- Dementia patients
- Dementia Advocates
- Dementia Caretakers
- Physicians
- Health Care Analysts
- Researchers in the field of Neurology
- Healthcare organizations
- Students
- All those providing care and treatment to patients with Dementia.

Topics to be focused

Track 1: Dementia and Brain Aging

Dementia is a chronic neurodegenerative disorder in which the complete deterioration of intellectual functioning and behavior occurs as progressive memory loss, Brain aging is a natural process that occurs as we get older, but certain factors can accelerate the rate at which it occurs.

In this session, the main aim is to understand the overview of dementia and its impact in order to explore the current research and potential solutions for managing and preventing the disease. Secondly, brain aging, its risk factors, and causes are addressed, and also about the research interventions to promote healthy brain aging are concentrated. we will also explore the connection between dementia and brain aging.

Track 2: Stages of Dementia

Dementia is a syndrome during which deterioration within the memory, allows and causes other problems within the brain.  The stages of dementia can vary depending on the specific type and the individual, but generally, the progression can be divided into three main stages: early, middle, and late. 

In this session, Understanding the stages of dementia is important in order to provide proper care and support for individuals affected by the disease. We hope this session will give clear information on the stages of dementia, its progression each stage, and the unique needs of individuals at each stage which is the aim behind this session.

Track 3: Neurology and Psychiatry

Neurology is the branch of medicine that deals with the diagnosis and treatment of disorders of the nervous system, including the brain and the spinal cord. Psychiatry, on the other hand, is the branch of medicine that deals with the diagnosis and treatment of mental illness, including mood and behavior disorders.

In this session, the latest research and developments in neurology and psychiatry related to dementia, the management of disease, as well as the role of neurology and psychiatry in taking care of patients with dementia which includes the management of behavioral and psychological changes, is discussed. It will be a great opportunity for all professionals and researchers in psychiatry, neurology and geriatrics, and related fields to learn, network, and share insights with scholars and experts in their respective fields.

Track 4: Neurological Brain Disorders

Neurological brain disorders are described as a disorder that affects the brain as well as the nerves found throughout the human body and the spinal cord. Structural, biochemical, or electrical abnormalities in the brain, spinal cord, or other nerves can result in a range of symptoms.

In this session, various neurological brain disorders, their causes, early diagnosis, the impact of the disease, and its treatment procedures are discussed.

Track 5: Neuropharmacology & Neurodegenerative Diseases

Neuropharmacology is a branch of the study of medicine that affects the nervous system. It is focused on the development of compounds that may be of benefit to individuals who suffer from neurological or psychiatric illnesses. Neurodegenerative diseases are characterized by the progressive loss of nerve cells in the brain, leading to a decline in cognitive function.

In this session, an in-depth understanding of neuropharmacology and neurodegenerative diseases is provided which paves ways to research futuristic improvement in treatment and care for the diseases.

Track 6: Alzheimer's Disease and Parkinson's Disease

Alzheimer's disease is a brain complaint that tentatively destroys memory and thinking skills and the ability to carry out the simplest tasks. The exact cause of Alzheimer's disease is not known, but it is believed to be a combination of genetic, lifestyle, and environmental factors. Parkinson's disease is a disorder of the nervous system that affects movement. Symptoms include temblors, stiffness, and difficulty with connection and balance.

In this session, it is elaborately discussed the disease, ongoing research on diagnosis advancements, treatments, and developing therapies for both diseases which will give a clear-cut idea about the diseases. 

Track 7: Huntington's Disease

Huntington's disease, also known as HD, is a rare but debilitating genetic disorder that affects the brain and nervous system. It is a rare, inherited disorder that causes the progressive breakdown and degeneration of nerve cells in the brain.

In this session, we will delve into the latest research and advancements in understanding and treating the disease. It also strikes a great opportunity to hear from leading experts in the field on Huntington's disease, early diagnosis, and recent advancements in treatments and care. Attendees will have an opportunity to gain knowledge about the disease and related topics to get a deeper understanding of the disease, its impact of the disease, and its relative measures to eliminate or lower the cause of the disease.

Track 8: Dementia with Lewy Bodies

Dementia with Lewy Bodies is a type of progressive dementia that affects 1-2% of the population over the age of 65. It is characterized by a combination of cognitive, motor, and behavioral symptoms that are caused by the presence of Lewy bodies, which are abnormal clumps of protein in the brain.

In this session, it is discussed about dementia, its symptoms, challenges in the diagnosis process, treatment, and managed care. Secondly, the session will focus on futuristic research on new techniques, imaging technologies for the diagnosis process, and new medications. It is necessary that healthcare professionals, researchers, and scholars are aware of the disease and its unique symptoms and treatments which are discussed in this session.

Track 9: Microglia in Dementia

Microglia are known as the immune cells of the central nervous system. Microglia plays an important part in the pathological process of Alzheimer's disorder.  Microglia are activated in the brains of individuals with Alzheimer's disease, and it also contributes to the formation of amyloid plaques and neurofibrillary tangles.

This session will focus on microglia and its role in dementia and its related disease in terms of progression, cause, etc., it will also explore recent research on the complex role of microglia in therapies and drugs which will give the attendees a better understanding of microglia and its implication in dementia and related diseases.

Track 10: Vascular Dementia and Stroke

Vascular dementia is a type of dementia caused by problems with the blood vessels that supply the brain. This type of dementia is often caused by strokes, which can damage the brain and lead to cognitive decline. Strokes are a leading cause of dementia. Research says that a person who had a stroke is at high risk of developing this type of dementia.

In this session, it is evident to discuss the latest research on vascular dementia and strokes, including risk factors, diagnosis, and treatment options including medications, therapies, and lifestyle changes that can help improve cognitive function and slow the progression of the disease. It will also be a great opportunity to hear from experts about their research and share their insights on the latest developments in the treatment of vascular dementia.

Track 11: Frontotemporal Dementia

Frontotemporal dementia is a relatively rare form of dementia that affects the front and temporal lobes of the brain. These areas of the brain are responsible for controlling behavior, language, and decision-making.

In this session, the latest research on frontotemporal dementia, including advances in understanding the underlying causes, and potential treatments are discussed. We hope this conference will provide valuable information and resources for those affected by the disease and help to raise awareness about the disease.

Track 12: Semantic Dementia and Mixed Dementia

Semantic dementia, also known as primary progressive aphasia, is a type of frontotemporal dementia that affects the brain's ability to understand and use words. Mixed dementia, on the other hand, is a combination of Alzheimer's disease and another form of dementia, such as semantic dementia or Lewy body dementia. Individuals with mixed dementia may experience a combination of symptoms, such as memory loss, language difficulties, and visual hallucinations.

In this session, the latest research and treatment options for individuals with semantic and mixed dementia are discussed. We will also have a panel discussion with experts whose insights can be great opportunities for individuals who have been affected by semantic and mixed dementia. It also gives attendees, healthcare individuals, and researchers a chance to gain insight and understanding of the disease which is the goal of this session.

Track 13: Mild Cognitive Impairment

Mild cognitive impairment is an early stage of memory loss or other cognitive capability loss which includes language or visual/spatial perception in people who maintain the ability to independently perform most activities of routine life. It is considered a risk factor for developing dementia, particularly Alzheimer's disease.

In this session, we will discuss the latest research on mild cognitive impairment, including risk factors, diagnosis, and treatment options, and the use of early intervention and prevention strategies for individuals with impairment. Studies have shown that lifestyle changes, such as regular physical activity and a healthy diet, can help slow the progression and reduce the risk of developing dementia. This conference will bring together leading experts in the field of dementia and mild cognitive impairment, including researchers, clinicians, and caregivers, to share the latest knowledge and best practices.

Track 14: Amyloid Protein in Dementia

Amyloid proteins are a group of proteins that can form aggregates in the brain, leading to the formation of plaques. These plaques are a hallmark of Alzheimer's disease, the most common form of dementia. Amyloid beta is the specific protein that is believed to be responsible for the formation of plaques in Alzheimer's disease.

In this session, discussions about the latest research findings, the underlying mechanisms, potential therapies, new imaging techniques for diagnosis, and further research on the role of amyloid protein in dementia and its relative diseases will be focused on. We hope that this session will provide valuable information on the related cause of the disease and the current state of research. we look forward to continued progress in the fight against dementia.

Track 15: Tau Protein in Dementia

Tau protein is a microtubule-associated protein that is found in the brain. It plays a vital role in the structure and function of neurons, helping to maintain the stability and shape of nerve cells. However, in individuals with dementia, tau protein can become abnormal and form into tangles that can damage and kill nerve cells.

In this session, we will delve into the role of tau protein in dementia and its causes, and treatments & also valuable information on the latest research and developments surrounding tau protein in dementia and that it will inspire further research and advancements in the treatment of the disease.

Track 16: Hearing Loss in Dementia

Hearing loss is a common problem in older adults and is even more prevalent in individuals with dementia. One of the main challenges in managing hearing loss in dementia is the difficulty in identifying and assessing the problem.

In this session, attendees will learn about the latest research on identifying and assessing hearing loss in dementia. They will also learn about its impact on the disease and its progression, identification, and communication strategies by using assistive technology which is the main aim of this session.

Track 17: Movement Disorders and Dementia

Movement disorders are a group of neurological conditions that affect the ability to control and coordinate movement. One of the most common movement disorders associated with dementia is Parkinson's disease which occurs due to the loss of dopamine-producing cells in the brain. There are also several other movement disorders that are associated with dementia, including progressive supranuclear palsy, and multiple system atrophy.

In this session, the discussion will be on movement disorders caused by dementia and its related diseases, and the symptoms of the disease. Secondly, we will focus on the ongoing research on the underlying mechanisms that link dementia and movement disorders. It is important for healthcare professionals, researchers, and attendees from related fields to be aware of the signs and symptoms of this complex link between dementia and movement disorders in order to develop effective treatments for the disease. 

Track 18: Dementia Models

Dementia is a complex and multifactorial disease, and different models have been developed to help understand its underlying mechanisms and test potential treatments. Dementia models mainly include animal models, computer models, and cellular models which are used by researchers in order to study dementia diseases.

In this session, we may discuss various dementia models which are used to study the effect, progression, and different factors such as genetics, environment, and lifestyle changes that contribute to the development of dementia. We hope this session will provide valuable information and insights to researchers, scientists, and healthcare professionals working in the field of dementia. It will also discuss the current and future developments in the field of dementia modeling and how they can aid in the understanding, diagnosis, and treatment of dementia.

Track 19: Convergent Mechanisms across Dementia

Convergent Mechanisms across Dementia will focus on the latest research and developments in understanding the underlying mechanisms of different types of dementia.

This session will bring together experts in the fields of neuroscience, psychiatry, and geriatrics to discuss the commonalities and differences in the underlying pathologies of dementia subtypes such as Alzheimer's disease, vascular dementia, and frontotemporal dementia which paves way for the attendees to network and share ideas with experts from a wide range of disciplines, including neuroscience, psychiatry, geriatrics, epidemiology, and genetics. This will include discussions on the use of non-pharmacological therapies, the role of caregivers and family members, and the need for policy and systems changes to improve the lives of people living with dementia which will provide an overview of the current state research on dementia.

Track 20: Modifiable Risk Factors

Modifiable risk factors refer to those factors that can be changed or controlled in order to reduce the risk of developing dementia. The major modifiable risk factors for dementia include cardiovascular health, High blood pressure, high cholesterol, diabetes, smoking, and obesity dementia.

In this session, we will discuss the modifiable risk factors of dementia and the necessary steps to control the progression of the disease and avoid those risk factors. 

Track 21: Dementia Diagnosis and Its Recent Advancements

Dementia is a devastating condition that affects millions of people worldwide, and the early and accurate diagnosis of dementia is crucial for the management and treatment of the disease. Recent advancements in the diagnosis process include the use of biomarkers and cognitive tests. In addition to these advancements, there is also a growing interest in the use of mobile technologies and telemedicine in the diagnosis of dementia.

In conclusion, the diagnosis of dementia is a complex and challenging task, but recent advancements in the diagnosis process will fasten the early signs of the disease which can speed up the treatment and care which is elaborately discussed in this session.

Track 22: Brain Stimulation and Imaging

Brain stimulation involves implanting electrodes that produce electrical impulses within certain areas of the brain to regulate abnormal impulses. Although producing such impulses causes damage to certain cells and chemicals within the brain. Imaging techniques, such as magnetic resonance imaging and positron emission tomography, allow researchers to visualize changes in the brain that occur with dementia.

In this session, the importance of both brain stimulation and imaging are discussed which are considered the major power tools in understanding the underlying causes of dementia and its further treatments.

Track 23: Bioinformatics Approach for Dementia

Bioinformatics is the application of computational and statistical methods to analyze biological data. It involves the use of large data sets, such as genetic information, to identify patterns and relationships that can inform the understanding and management of the disease.

In this session, we will discuss the bioinformatics approach and its need in analyzing dementia diseases and their progression. It also focuses on the application of the bioinformatics approach in the identification of genetic information which can be used in understanding the underlying biology of the disease and developing new therapies, treatments, and management of the disease.

Track 24: Biomarkers for Dementia

Biomarkers are biological indicators that can be used to diagnose a specific condition or disease. In the case of dementia, biomarkers such as brain imaging, genetic testing, and cerebrospinal fluid analysis are being used to identify the early signs of the disease.

In this session, we will discuss dementia and the impact of the disease. It will also focus on the reliable need for biomarkers, current biomarkers, their advantages, and limitations. This session will also discuss current research on biomarker development and challenges in developing dementia. Then, the use of biomarkers and their significance which include future advancements in order to improve the process of diagnosis and further prevention is discussed.

Track 25: Novel Therapeutics and Drug Targets for Dementia

Novel therapeutics refers to new and innovative treatments that have the potential to improve the lives of individuals living with dementia. These can include drugs, devices, and other interventions that target specific mechanisms underlying the disease including immune therapy, anti-inflammatory drugs, neuroprotective agents, and gene therapy.

In this session, it is discussed about the search for novel therapeutics and drug targets for dementia is a critical area of research that holds great promise for improving the lives of individuals living with this debilitating condition.

Track 26: Design and Implementation of Clinical Trials & Case Reports

Clinical trials are essential for evaluating the safety and efficacy of new treatments for dementia. These studies involve recruiting participants and administering a specific intervention or medication to determine its effectiveness. Case reports provide detailed descriptions of individual patient experiences. These reports can be useful in identifying new treatment options or understanding how a specific treatment may affect different individuals.

In this session, the design and implementation of the clinical trials and case reports are discussed, while clinical trials can provide statistically significant results, they may not always provide a complete picture of how treatment may affect different individuals. Case reports, on the other hand, can provide detailed information about a specific individual's experience. On the whole, the importance of clinical trials and case reports and their needs are discussed.

Track 27: Dementia Nursing and Care

Dementia nursing and care is an essential aspect of providing care for individuals with dementia. Dementia is a progressive brain disorder that affects individual memory, thinking, and behavior. It is a challenging condition that requires specialized care, and nurses play a vital role in providing that care.

In this session, we will delve into the latest research and best practices in dementia nursing and dementia care. We will discuss the various stages of dementia, including early onset, middle stage, and advanced stage, and the unique challenges that each stage presents. We will also explore the different types of dementia, such as Alzheimer's disease and vascular dementia, and the impact they have on an individual's life. In conclusion, dementia nursing and care is a critical aspects of providing care for individuals with dementia. The main focus will be on the information regarding the latest research and best practices in dementia nursing and care will be discussed. It will also enrich them with a deeper understanding of the importance of person-centered care for individuals with dementia and the skills to provide that care.

Track 28: Dementia Care and Policy

Dementia care and policy are two critical areas that are closely interlinked and have a significant impact on the lives of dementia-affected people and their families.

In this session, we intrude to bring experts in the field of dementia care and policy to discuss the latest research, best practices, urge for early diagnosis of the disorder, and emerging trends in this area. Those care and policies include strategies for providing quality care for individuals living with dementia, technological and community-based improvement in care, and support for them. Overall, this session will provide a valuable opportunity for professionals in the field of dementia care and policy to come together, share knowledge, and collaborate on ways to improve the lives of dementia-affected individuals.

Track 29: Dementia Rehabilitation

Dementia rehabilitation is an important aspect of caring for individuals with dementia, as it aims to improve their quality of life and maintain their independence. The focus of dementia rehabilitation is on helping individuals with dementia to maintain their cognitive, physical, and social abilities, and manage the symptoms of their condition.

In this session, we will discuss various rehabilitation aspects that help individuals with dementia to manage the disease. It will also focus on the number of strategies that will help the affected individuals to improve their quality of life and maintain their independence.

Track 30: Dementia care management

Dementia care management is a kind of cooperative care, defined as a complex intervention aiming to give optimal treatment and care for individuals with dementia and support caregivers using a computer-aided assessment determining a personalized array of intervention modules and subsequent success monitoring.

In this session, we will discuss the latest research on best practices and strategies for dementia care management. It will also focus on addressing physical safety concerns, emotional and psychological needs, and therapies to manage dementia. It will also address the importance of providing a safe and supportive environment for individuals living with dementia to help manage dementia symptoms and improve their quality of life.

Track 31: Prevention Measures and Awareness

Prevention measures and awareness are crucial in the fight against dementia. By understanding the risk factors for dementia and taking steps to reduce them, we can help to prevent or delay the onset of the condition. Effective prevention measures include a healthy diet, regular fitness, managing chronic conditions, managing stress, etc.,

In this session, we will discuss the importance to raise awareness about the signs and symptoms of dementia, as well as the available treatments and support options that can be done through public education campaigns, community outreach programs, and support groups for those affected by dementia. With the right prevention measures and awareness, we can help to reduce the impact of dementia on individuals and families around the world which is discussed in this session.

Dementia Care Market Analysis


Dementia is a progressive decline in cognitive abilities that affects millions of people worldwide, and it is becoming an increasingly important public health issue as the population ages. Dementia is not a normal part of aging, but age is the most significant risk factor for its development. The major reasons for the increase in dementia are likely to be population growth and aging. Dementia results from a variety of conditions and injuries that affects the brain in the first place. Alzheimer's disease is the most common form of dementia which contributes to 60-70% of cases. Dementia is currently the seventh leading cause of death among all disorders and one of the major causes of disability and reliance among older people worldwide. 
The dementia market is expected to grow significantly due to an increasingly aging population, a rise in the incidence of Alzheimer's disease and related disorders, and advancements in treatments and diagnostic methods. The global dementia market size was valued at USD 8.4 billion in 2020 and is expected to reach USD 14.5 billion by 2023, growing at a CAGR of 11.2% during the forecast period. According to recent research, there are nearly 10 million new cases every year and more than 55 million are living with dementia. When it comes to global statistics, more than 153 million people are expected to be living with dementia by the year 2050 which is triple the current rate. Deaths due to dementia in the later 75’s are doubled in the last 10 years. The mortality rate of elderly people due to any type of dementia is higher than those without dementia.
Dementia-affected countries on basis of patient rate are as follows: the first country is Finland with 54.65%, the second country is the United Kingdom with 42.7% which are further followed by Slovakia with 38.15%, Albania at 36.9%, Iceland at 35.59%, Brunei with 33.87%, Netherlands with 33.78%, united states with 33.26% so on. In order to suppress the increasing rate of dementia, it is necessary to develop new drugs, treatments, and therapies for managing and avoiding the disease.

Drug Market Insights

The global dementia drugs market is anticipated to register a CAGR of 8.2% over the cast period. The factors propelling the changes are adding prevalence of target conditions, launching new and innovative technologies, and medicines, and increase in government backing and awareness programs for dementia. The Dementia Drug Marketplace is Segmented by Indications (Lewy Body Dementia, Parkinson’s Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and so on), technology (high throughput screening, pharmacogenomics, combinatorial chemistry, nanotechnology, and other technologies), end-user (pharmaceutical companies, contract research organizations (CROs), and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).
The Alzheimer's disorder segment is expected to hold a major market share over the cast period owing to factors similar to the increasing burden of Alzheimer's disease and ongoing research & developing medicines for Alzheimer's. The increasing company focus on exploring & initiating the development of effective treatment medicines for patients with Alzheimer's disorder is anticipated to drive the segment growth over the period. 

Drug Market Analysis in the USA

As per the Alzheimer’s Association 2021 report, the United States Food and Drug Administration (FDA) approved five medicines for treating Alzheimer’s which include rivastigmine, galantamine, donepezil, memantine, and memantine combined with donepezil. As per the same source, mostly, Alzheimer’s dementia is diagnosed only in people aged 65 years or older. This is called late-onset Alzheimer’s. In the United States, nearly 5.3% of people aged between 65 to 74, 13.8% of people aged 75 to 84, and 34.6% of people aged 85 or older have Alzheimer’s dementia. Earlier research states that 6.2 million Americans aged 65 years and older were living with Alzheimer’s dementia in 2021 and are projected to reach 13.5 million by 2050. Such a high prevalence of the disorder is anticipated to bolster the demand for dementia medicines among the patient population over the period.

Drug Market Analysis in the UK

The European region will hold a major market share in the upcoming years owing to factors such as the rise in the burden of neurological disorders in countries like the United Kingdom and Germany, the growth in strategic development by the key players, and upgrading government initiatives.
As per February 2022 update by the United Kingdom government, the dementia, and Alzheimer’s diagnosis rate was 62.4% in the United Kingdom in 2020, which indicates the rise of the patient pool within the country, which, in turn, creates the demand for medicines in the United Kingdom.
Likewise, as per the 2021 National Dementia Strategy, in Germany, 1.6 million people were affected by the disorder in 2020. As per the same source, dementia is detected in one person per 25 households, and the number is expected to increase to 2.8 million people by 2050. Thus, the increasing incidences of disorder among the European population are likely to propel the demand for dementia medicines in the European region, thereby contributing to market growth.

Impact of Covid-19 on the Drug Market

The outbreak of the COVID-19 epidemic had a considerable impact on the drug market. Certain countries saw significant interruptions in the delivery of pharmacological remedies to dementia-affected people. According to a study published in Alzheimer's and Dementia in October 2021, 68.6% of sales has been increased compared to the prior year. In March 2020, countries increased consumption volume by 82.3% in 34 European and North American countries. Business rose during the pre-pandemic period, with the most apparent prick occurring in March. During the epidemic, use was lower in April and May but increased in June which significantly impacted the growth. However, since the restrictions were lifted, the assiduity has been recovering well. Over the last two years, the recovery has been led by the high prevalence of disease and new product launches.

Treatment Insights

The dementia treatment market is expected to grow significantly in 2023 due to the increasing prevalence of dementia worldwide. The market is driven by factors such as increasing awareness about the disease, advancements in medical technology, and the growing aging population. Currently, there is no cure for dementia, but various treatments and therapies are available to help manage its symptoms and slow down its progression. These include drugs such as cholinesterase inhibitors and memantine, as well as non-pharmacological therapies such as cognitive stimulation therapy and physical exercise. The market for dementia treatments is dominated by several large pharmaceutical companies, but with the number of start-up companies and smaller companies entering the market with innovative solutions, it is a great deal. In 2023, it is expected that the market for dementia treatments will continue to grow, with new drugs and therapies being developed and approved for use. Additionally, the increasing demand for home-based care and telemedicine solutions is expected to drive growth in the market for non-pharmacological therapies.

Regional Insights

There are currently more than 900,000 dementia-affected people in the UK and it is predicted that this figure will be more than 1.6 million by 2024. According to the current research, 1 in 14 individuals over the age of 60 has dementia. In response to this growing need, the UK government has made a commitment to improving support for those living with dementia. This includes increased funding for research into the causes and treatments of dementia and the development of new and innovative approaches to care and support.
Dementia is a growing concern in the United States, with an estimated 5.7 million people living with the condition in 2023. The number is expected to rise to nearly 14 million by 2050, as the population ages and more people live longer. The cost of caring for individuals with dementia is also increasing, with estimates suggesting that it will reach over $290 billion by 2023. Mostly, the cost is shouldered by families and caregivers, as well as the government through Medicaid and Medicare programs. In response to the growing prevalence of dementia, the U.S. government has increased funding for research into the causes, treatments, and potential cures for the condition. Additionally, there have been efforts to improve access to care and support services for individuals living with dementia and their families.

Key Players

The dementia market is moderately competitive and consists of local and global players. The key players have been investing in new product development, collaborations, and strategic alliances similar to mergers and acquisitions to enhance their market position. Major key players include Apotex Inc., AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Teva Pharmaceuticals, and Zydus Cadila, among others.

Why London?

London is a fascinating city laden with history, filled with art galleries, ancient attractions, beautiful green parks, fantastic shopping and dining, a vibrant theatre scene, and royalty. London is known for being the world's top university. In recent years, London has become a hub for higher education, attracting students from around the world to study at its universities. The city is known for its cosmopolitan atmosphere, rich cultural heritage, and excellent employment prospects, making it a popular and multifaceted destination on enormous notes. 


Speakers Interview